Moberg Pharma AB (publ) (MOB) Q3 2024 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Moberg Pharma Ab.

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.233 -- 00:00:03.056 Good morning all, good afternoon all, and welcome to the Movericks Family Conference 00:00:03.056 -- 00:00:06.100 call. My name is Adam and I'll be your operator today. 00:00:06.100 -- 00:00:09.464 If you'd like to ask a question in the Q&A portion of today's call, please press star 00:00:09.464 -- 00:00:13.469 followed by 1 on your telephone keypad. I'll now hand the call to Anna Young to begin. 00:00:13.469 -- 00:00:16.710 So Anna, please go ahead when you are ready. 00:00:16.813 -- 00:00:21.058 Thank you, and welcome everyone to this telephone conference following the press release 00:00:21.058 -- 00:00:26.044 yesterday evening. Please note that this call will be recorded and will be made available 00:00:26.044 -- 00:00:31.141 on our webpage. With me today are our Chief Medical Officer Anders Bergessinger 00:00:31.141 -- 00:00:34.605 and our Chief Scientific Officer Amir Tavakol. 00:00:34.605 -- 00:00:38.990 Today, we will provide an important update on our ongoing efforts related to our product 00:00:38.990 -- 00:00:44.117 MOB15. We understand that there is a significant interest in the progress of this program, 00:00:44.117 -- 00:00:48.262 and we aim to be as clear, transparent, and forthcoming as possible. 00:00:48.262 -- 00:00:52.367 Our objective is to address not only the applying results from our North American Play 00:00:52.367 -- 00:00:57.533 Treats study, but also preliminary statistics strategic implications that arise 00:00:57.533 -- 00:01:02.558 from the data. However, I want to emphasize that this is top-line data that we have 00:01:02.558 -- 00:01:07.382 just received, and both we and our partners need time to thoroughly analyze and digest 00:01:07.382 -- 00:01:10.924 the information before making conclusions. 00:...